PNPLA3 I148M variant is the main driver of weight gain after hepatitis C cure
Jazyk angličtina Země Anglie, Velká Británie Médium electronic
Typ dokumentu časopisecké články
Grantová podpora
IN 00023001
Ministerstvo Zdravotnictví Ceské Republiky
PubMed
40665131
PubMed Central
PMC12264105
DOI
10.1038/s41598-025-11085-9
PII: 10.1038/s41598-025-11085-9
Knihovny.cz E-zdroje
- Klíčová slova
- PNPLA3, Direct-acting antivirals, Hepatitis C virus, Weight gain,
- MeSH
- alely MeSH
- antivirové látky terapeutické užití škodlivé účinky MeSH
- chronická hepatitida C * farmakoterapie genetika MeSH
- dospělí MeSH
- genotyp MeSH
- hmotnostní přírůstek * genetika MeSH
- index tělesné hmotnosti MeSH
- jednonukleotidový polymorfismus MeSH
- lidé středního věku MeSH
- lidé MeSH
- lipasa * genetika MeSH
- membránové proteiny * genetika MeSH
- senioři MeSH
- studie případů a kontrol MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- acyltransferasy MeSH
- antivirové látky MeSH
- fosfolipasy A2 nezávislé na vápníku MeSH
- lipasa * MeSH
- membránové proteiny * MeSH
- PNPLA3 protein, human MeSH Prohlížeč
BMI increase is commonly described in patients after chronic hepatitis C (HCV) cure with direct-acting antivirals. The aims of our study were to confirm the BMI increase compared with a population control group and to search for the allelic association between BMI increase and PNPLA3 gene I148M variant (G allele) carriage. We compared the BMI increase in 230 patients (HCV group) 3 years after the end of anti-HCV treatment with a group of 640 healthy subjects (controls) within the same period. The median BMI increase in the HCV group was 0.39 (range - 6.5-11.8), 0.70 in controls (-6.3 - 14.0); the difference was not significant (p = 0.95). However, the HCV subgroups showed significant difference according to PNPLA3 genotype: CC 0.0 (-6.5-8.7) vs. CG + GG 0.94 (-4.2-11.8), p = 0.0045, in contrast to the subgroups of controls: CC 0.7 (-5.1-13.7) vs. CG + GG 0.7 (-0.3-14.90), p = 0.86. BMI increase in the HCV subgroup CC + CG was significantly higher than in the entire control group (p = 0.035), whereas the HCV subgroup CC did not differ from controls (p = 0.07). The BMI increase was associated with PNPLA3 G allele carriage in the allelic model and the multivariate analysis.
1st Faculty of Medicine Charles University Prague Czech Republic
3rd Faculty of Medicine Charles University Prague Czech Republic
Zobrazit více v PubMed
European Association for the Study of the Liver. Electronic address, E. E. E., Clinical Practice Guidelines Panel & representative, C. E. G. B. & Panel, M. EASL recommendations on treatment of hepatitis C: Final update of the series. PubMed
Younossi, Z. M. et al. Long-term benefits of sustained virologic response for patient-reported outcomes in patients With chronic hepatitis C virus infection. PubMed
Mohanty, A., Salameh, S. & Butt, A. A. Impact of direct acting antiviral agent therapy upon extrahepatic manifestations of hepatitis C virus infection. PubMed
Schlevogt, B. et al. Weight gain after interferon-free treatment of chronic hepatitis C-Results from the German hepatitis C-Registry (DHC-R). PubMed PMC
Do, A. et al. Excess weight gain after cure of hepatitis C infection with Direct-Acting antivirals. PubMed PMC
El Kassas, M. et al. A significant upsurge of body mass index in patients with chronic hepatitis C successfully treated with direct-acting antiviral regimens. PubMed PMC
Chen, C. H. et al. Weight gain and increased body mass index in patients with hepatitis C after eradication using direct-acting antiviral therapy in Taiwan. PubMed PMC
Nkwocha, C. L., Carter, P. S., Blair, S., Blackwell, J. M. & Fasanmi, E. O. Understanding the effect of direct-acting antiviral therapy on weight in patients with chronic hepatitis C. PubMed
Romeo, S. et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. PubMed PMC
Li, J. Z. et al. Chronic overexpression of PNPLA3I148M in mouse liver causes hepatic steatosis. PubMed PMC
Tardelli, M. et al. Absence of adiponutrin (PNPLA3) and monoacylglycerol lipase synergistically increases weight gain and aggravates steatohepatitis in mice. PubMed PMC
Yang, A., Mottillo, E. P., Mladenovic-Lucas, L., Zhou, L. & Granneman, J. G. Dynamic interactions of ABHD5 with PNPLA3 regulate triacylglycerol metabolism in brown adipocytes. PubMed PMC
Cinque, F. et al. Interaction between lifestyle changes and PNPLA3 genotype in NAFLD patients during the COVID-19 lockdown. PubMed PMC
Wilson, P. A., Gardner, S. D., Lambie, N. M., Commans, S. A. & Crowther, D. J. Characterization of the human patatin-like phospholipase family. PubMed
Wieser, V. et al. Weight loss induced by bariatric surgery restores adipose tissue PNPLA3 expression. PubMed
Huang, Y. et al. A feed-forward loop amplifies nutritional regulation of PNPLA3. PubMed PMC
Liu, Z. et al. Causal relationships between NAFLD, T2D and obesity have implications for disease subphenotyping. PubMed PMC
Davis, J. N. et al. Increased hepatic fat in overweight Hispanic youth influenced by interaction between genetic variation in PNPLA3 and high dietary carbohydrate and sugar consumption. PubMed PMC
Cifkova, R. et al. Longitudinal trends in major cardiovascular risk factors in the Czech population between 1985 and 2007/8. Czech MONICA and Czech post-MONICA. PubMed
Krawczyk, M., Stachowska, E., Milkiewicz, P., Lammert, F. & Milkiewicz, M. Reduction of caloric intake might override the prosteatotic effects of the PNPLA3 p.I148M and TM6SF2 p.E167K variants in patients with fatty liver: Ultrasound-Based prospective study. PubMed
Frankova, S., Uzlova, N., Merta, D., Pitova, V. & Sperl, J. Predictors of significant liver fibrosis in people with chronic hepatitis C who inject drugs in the Czech Republic. PubMed PMC
LSM by VCTE™ Interpretation Guide. https://www.echosens.com/wp-content/uploads/2021/01/Interpretation-Guide-2020.pdf (2020).
